Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.
Van Besien
Koen
K
Smith
Sonali
S
Anastasi
John
J
Larson
Richard
R
Thirman
Michael
M
Odenike
Toyosi
T
Stock
Wendy
W
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D042381:Granulocyte Precursor Cells / Q000187:drug effects; D006402:Hematologic Diseases / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008558:Melphalan / Q000009:adverse effects*; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000009:adverse effects; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives*
D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan